AOA Dx

AOA Dx is developing the next frontier in early-stage cancer detection through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocateTM, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx has developed AKRIVIS GDTM, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of womens health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combi...